{ "$schema_version": "5.3", "review_mode": "fresh", "claim_restatement": { "index_wording": "Grey-market GLP-1 Analogues", "entry_form": "claim", "gradeable_restatement": "Research-chemical-sourced GLP-1 analogues deliver the efficacy demonstrated in registrational trials.", "restatement_required": true, "split_into": [], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "Enrollment, product identity, disease, species, baseline state and treatment timing", "determinable_before_outcome": true, "determined_from": "Enrollment and experimental design, before results; no responder-defined scope.", "action": "retained" } ] }, "hypothesis": { "name": "Grey-market GLP-1 Analogues", "central_claim": "Research-chemical-sourced GLP-1 analogues deliver the efficacy demonstrated in registrational trials.", "proposed_mechanism": "Research-chemical-sourced GLP-1 analogues deliver the efficacy demonstrated in registrational trials.", "claimed_scope": "Research-chemical products, their supply reliability and clinical equivalence to the tested regulated products", "claimed_level": [ "progression" ], "is_conjunctive": true, "conjunctive_note": "The website claim hinges on SC3 at its stated scope; SC1 and SC2 are reported separately and cannot substitute for that claim." }, "rubric_routing": { "primary_rubric": "06-metabolism-aging.md", "secondary_rubrics": [], "index_notes_applied": [ "The website claim hinges on SC3 at its stated scope; SC1 and SC2 are reported separately and cannot substitute for that claim." ], "rubric_fit_note": "06-metabolism-aging is the closest metabolic rubric, but its organismal-aging language is a poor fit to supply-chain equivalence. The universal ladder and causal-scope rules govern the nominal product claim. SC1 includes randomized clinical/functional outcomes, not weight biomarkers alone. SC2 and SC3 do not inherit aging-specific thresholds. The initially listed psychiatry secondary rubric was removed before adjudication as irrelevant; the original preregistration is retained unchanged." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Regulated GLP-1 receptor agonist products causally improve body weight and metabolic outcomes.", "subclaim_type": "mechanism", "scope": "Trial-defined regulated products", "claimed_scope": "Trial-defined regulated products", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Randomized regulated-product trials", "hsef_level": "Ε", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Randomized authentic products change weight and metabolic trajectories; selected trials also improve clinical kidney, cardiovascular and functional outcomes. Ε is restricted to trial products and tested populations, not arbitrary molecules bearing their names." }, { "id": "SC2", "statement": "Research-chemical supply reliably delivers the identity, purity, concentration and sterility of trial products.", "subclaim_type": "generalization", "scope": "Unregulated products sold online", "claimed_scope": "Unregulated products sold online", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Independent product analytical testing", "hsef_level": "Β", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Small product assays and adverse-event observations establish measured mismatches, not reliable exposure across an unregulated market. The reliability proposition remains associational and is challenged, rather than causally established." }, { "id": "SC3", "statement": "Unregulated research-chemical products reproduce the clinical efficacy of trial products.", "subclaim_type": "generalization", "scope": "People using unregulated products", "claimed_scope": "People using unregulated products", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Prospective authenticated-product clinical comparisons", "hsef_level": "Α", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "No selected controlled clinical comparison establishes research-chemical product efficacy equivalent to the trial formulations. Transferring a known molecule’s trial efficacy to unverified exposure is a narrative extrapolation." } ], "aggregation_rule": "primary-subclaim", "aggregation_preregistered": true, "aggregation_rationale": "The website claim hinges on SC3 at its stated scope; SC1 and SC2 are reported separately and cannot substitute for that claim.", "primary_subclaim_id": "SC3", "aggregation_derivation": "Overall Α applies to SC3, the preregistered clinical-equivalence proposition. It does not deny the efficacy of regulated GLP-1 medicines or prove that every research-market preparation is inactive. Product identity, exposure and clinical equivalence cannot be supplied by a chemical label or transferred from a registrational trial.", "aggregation_alternatives": { "weakest_link_would_return": "Α", "primary_subclaim_would_return": "Α", "scope_matched_would_return": "Α", "note": "Separate narrow successes do not replace the preregistered gate." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M2", "is_nominal": false, "name": "Authentic-product pharmacology with exposure-dependent effects", "core_claim": "Known formulation and verified delivery determine the tested therapeutic effect.", "explains_what_nominal_does_not": "Known formulation and verified delivery determine the tested therapeutic effect.", "strongest_supporting_evidence": [ "Randomized weight and clinical-outcome trials support authentic formulations." ], "strongest_contradictory_evidence": [ "This does not guarantee every supplier, batch, dose or clinical population." ], "hsef_level_for_this_model": "Ε", "rationale": "Randomized weight and clinical-outcome trials support authentic formulations. This does not guarantee every supplier, batch, dose or clinical population." }, { "rank_in_tournament": 2, "model_id": "M3", "is_nominal": false, "name": "Variable identity, formulation and administration", "core_claim": "Supply and administration variation can change exposure independently of the advertised target.", "explains_what_nominal_does_not": "Supply and administration variation can change exposure independently of the advertised target.", "strongest_supporting_evidence": [ "Direct online-product assays and a counterfeit case demonstrate possible mismatches." ], "strongest_contradictory_evidence": [ "Small selected samples and reporting systems cannot quantify the whole market." ], "hsef_level_for_this_model": "Β", "rationale": "Direct online-product assays and a counterfeit case demonstrate possible mismatches. Small selected samples and reporting systems cannot quantify the whole market." }, { "rank_in_tournament": 3, "model_id": "M1", "is_nominal": true, "name": "Research-market clinical equivalence", "core_claim": "The advertised peptide label is treated as sufficient to transfer trial efficacy.", "explains_what_nominal_does_not": "The advertised peptide label is treated as sufficient to transfer trial efficacy.", "strongest_supporting_evidence": [ "Some purchased samples contained semaglutide and licensed products work." ], "strongest_contradictory_evidence": [ "Presence does not establish purity, potency, exposure, sterility or clinical equivalence." ], "hsef_level_for_this_model": "Α", "rationale": "Some purchased samples contained semaglutide and licensed products work. Presence does not establish purity, potency, exposure, sterility or clinical equivalence." }, { "rank_in_tournament": 4, "model_id": "M4", "is_nominal": false, "name": "Expectation, co-use and selection", "core_claim": "Self-reported outcomes may reflect other interventions or selective reporting.", "explains_what_nominal_does_not": "Self-reported outcomes may reflect other interventions or selective reporting.", "strongest_supporting_evidence": [ "Qualitative use reports document co-use and unverified sourcing." ], "strongest_contradictory_evidence": [ "No adequate comparator quantifies this contribution." ], "hsef_level_for_this_model": "Β", "rationale": "Qualitative use reports document co-use and unverified sourcing. No adequate comparator quantifies this contribution." } ], "tournament_summary": "Descriptive comparison; does not modify the nominal score. An independently assayed, formulation- and exposure-controlled clinical comparison would separate authentic equivalent exposure from variable supply. Existing registrational trials do not provide that comparison.", "study_separating_rank1_from_rank2": "An independently assayed, formulation- and exposure-controlled clinical comparison would separate authentic equivalent exposure from variable supply. Existing registrational trials do not provide that comparison.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "n": 1, "pmid": "39509151", "title": "Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study.", "citation": "Ashraf AR, Mackey TK, Vida RG et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of medical Internet research. 2024.", "doi": "10.2196/65440", "pmcid": "PMC11582493", "url": "https://pubmed.ncbi.nlm.nih.gov/39509151/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39509151/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID39509151", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:Results:paragraph15, 2:Results:paragraph27, 2:Results:paragraph28, 2:Results:paragraph32. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Purchased online semaglutide samples contained the named peptide but had analytical and label mismatches.", "what_it_does_not_show": "Three delivered samples cannot estimate market-wide reliability; purity measurements do not identify the toxicity of every impurity. Two endotoxin results in the body are upper bounds, not quantified concentrations.", "confounders_present": [ "Three delivered samples cannot estimate market-wide reliability; purity measurements do not identify the toxicity of every impurity. Two endotoxin results in the body are upper bounds, not quantified concentrations." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 2, "pmid": "40285721", "title": "Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.", "citation": "McCall KL, Mastro Dwyer KA, Casey RT et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert opinion on drug safety. 2026.", "doi": "10.1080/14740338.2025.2499670", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40285721/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40285721/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID40285721", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Compounded GLP-1 adverse-event reports disproportionately included quality and administration problems.", "what_it_does_not_show": "Spontaneous reporting odds are not incidence; compounded and research-market products are different categories.", "confounders_present": [ "Spontaneous reporting odds are not incidence; compounded and research-market products are different categories." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 3, "pmid": "37735340", "title": "Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting.", "citation": "Alabduljabbar K, Alsaqaaby M, Neff KJ et al. Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting. Endocrine. 2024.", "doi": "10.1007/s12020-023-03534-0", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37735340/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37735340/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID37735340", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Prescribed semaglutide was associated with weight loss in clinical practice.", "what_it_does_not_show": "An observational prescription cohort does not test unregulated products or eliminate attrition bias.", "confounders_present": [ "An observational prescription cohort does not test unregulated products or eliminate attrition bias." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 4, "pmid": "38976257", "title": "Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.", "citation": "Rodriguez PJ, Goodwin Cartwright BM, Gratzl S et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA internal medicine. 2024.", "doi": "10.1001/jamainternmed.2024.2525", "pmcid": "PMC11231910", "url": "https://pubmed.ncbi.nlm.nih.gov/38976257/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38976257/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID38976257", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "A matched prescription cohort associated tirzepatide with greater weight loss than semaglutide.", "what_it_does_not_show": "Residual confounding and treatment discontinuation remain; neither product was an unregulated comparator.", "confounders_present": [ "Residual confounding and treatment discontinuation remain; neither product was an unregulated comparator." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 5, "pmid": "37952131", "title": "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.", "citation": "Lincoff AM, Brown-Frandsen K, Colhoun HM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England journal of medicine. 2023.", "doi": "10.1056/NEJMoa2307563", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37952131/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37952131/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SELECT", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "SELECT randomized semaglutide reduced cardiovascular events in obesity with prior cardiovascular disease.", "what_it_does_not_show": "This is regulated-product efficacy in a selected high-risk population, not identity or bioequivalence of online vials.", "confounders_present": [ "This is regulated-product efficacy in a selected high-risk population, not identity or bioequivalence of online vials." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: SELECT" ] }, { "n": 6, "pmid": "40353578", "title": "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.", "citation": "Aronne LJ, Horn DB, le Roux CW et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. The New England journal of medicine. 2025.", "doi": "10.1056/NEJMoa2416394", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40353578/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40353578/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT05822830", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "SURMOUNT-5 randomized comparison favored tirzepatide over semaglutide for weight loss.", "what_it_does_not_show": "Open-label comparison and dual receptor pharmacology do not establish equivalence of research-sourced molecules.", "confounders_present": [ "Open-label comparison and dual receptor pharmacology do not establish equivalence of research-sourced molecules." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 7, "pmid": "40934115", "title": "Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.", "citation": "Wharton S, Lingvay I, Bogdanski P et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. The New England journal of medicine. 2025.", "doi": "10.1056/NEJMoa2500969", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40934115/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40934115/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT05564117", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "OASIS-4 found weight reduction with the tested oral semaglutide formulation.", "what_it_does_not_show": "Formulation-specific trial results cannot establish absorption or efficacy of a different product.", "confounders_present": [ "Formulation-specific trial results cannot establish absorption or efficacy of a different product." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 8, "pmid": "39476339", "title": "Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.", "citation": "Bliddal H, Bays H, Czernichow S et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England journal of medicine. 2024.", "doi": "10.1056/NEJMoa2403664", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39476339/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39476339/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT05064735", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "STEP-9 improved weight, knee pain and function with semaglutide in obesity and knee osteoarthritis.", "what_it_does_not_show": "Weight mediation and the selected clinical context remain; unregulated sourcing was not tested.", "confounders_present": [ "Weight mediation and the selected clinical context remain; unregulated sourcing was not tested." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 9, "pmid": "33567185", "title": "Once-Weekly Semaglutide in Adults with Overweight or Obesity.", "citation": "Wilding JPH, Batterham RL, Calanna S et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. 2021.", "doi": "10.1056/NEJMoa2032183", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/33567185/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33567185/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT03548935", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "STEP-1 demonstrated weight loss with randomized regulated semaglutide.", "what_it_does_not_show": "Authentic trial-product exposure is the controlled variable; a supplier's chemical name alone is not that exposure.", "confounders_present": [ "Authentic trial-product exposure is the controlled variable; a supplier's chemical name alone is not that exposure." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 10, "pmid": "36322838", "title": "Once-Weekly Semaglutide in Adolescents with Obesity.", "citation": "Weghuber D, Barrett T, Barrientos-Pérez M et al. Once-Weekly Semaglutide in Adolescents with Obesity. The New England journal of medicine. 2022.", "doi": "10.1056/NEJMoa2208601", "pmcid": "PMC9997064", "url": "https://pubmed.ncbi.nlm.nih.gov/36322838/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36322838/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT04102189", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "STEP-TEENS reduced BMI with semaglutide in adolescents.", "what_it_does_not_show": "Developmental context and BMI endpoints differ from adult outcomes; no online-product comparison.", "confounders_present": [ "Developmental context and BMI endpoints differ from adult outcomes; no online-product comparison." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 11, "pmid": "36216945", "title": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.", "citation": "Garvey WT, Batterham RL, Bhatta M et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature medicine. 2022.", "doi": "10.1038/s41591-022-02026-4", "pmcid": "PMC9556320", "url": "https://pubmed.ncbi.nlm.nih.gov/36216945/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36216945/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT03693430", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "STEP-5 showed sustained weight loss over two years with semaglutide.", "what_it_does_not_show": "Sustained trial efficacy does not establish batch consistency elsewhere.", "confounders_present": [ "Sustained trial efficacy does not establish batch consistency elsewhere." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 12, "pmid": "33755728", "title": "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.", "citation": "Rubino D, Abrahamsson N, Davies M et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.", "doi": "10.1001/jama.2021.3224", "pmcid": "PMC7988425", "url": "https://pubmed.ncbi.nlm.nih.gov/33755728/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33755728/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT03548987", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "STEP-4 continuation maintained weight loss whereas withdrawal led to regain.", "what_it_does_not_show": "The randomized population completed a tolerability run-in; withdrawal of an authentic product is not a supply-chain test.", "confounders_present": [ "The randomized population completed a tolerability run-in; withdrawal of an authentic product is not a supply-chain test." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 13, "pmid": "35658024", "title": "Tirzepatide Once Weekly for the Treatment of Obesity.", "citation": "Jastreboff AM, Aronne LJ, Ahmad NN et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine. 2022.", "doi": "10.1056/NEJMoa2206038", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35658024/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SURMOUNT1", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "SURMOUNT-1 demonstrated weight reduction with tirzepatide.", "what_it_does_not_show": "Dual GIP/GLP-1 action and regulated manufacture cannot be assigned to an unassayed vial.", "confounders_present": [ "Dual GIP/GLP-1 action and regulated manufacture cannot be assigned to an unassayed vial." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: SURMOUNT1" ] }, { "n": 14, "pmid": "38078870", "title": "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.", "citation": "Aronne LJ, Sattar N, Horn DB et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.", "doi": "10.1001/jama.2023.24945", "pmcid": "PMC10714284", "url": "https://pubmed.ncbi.nlm.nih.gov/38078870/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38078870/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT04660643", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "SURMOUNT-4 continuation and withdrawal separated weight trajectories.", "what_it_does_not_show": "Run-in selection restricts generality; the trial does not establish unregulated equivalence.", "confounders_present": [ "Run-in selection restricts generality; the trial does not establish unregulated equivalence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 15, "pmid": "38819983", "title": "Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.", "citation": "Zhao L, Cheng Z, Lu Y et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024.", "doi": "10.1001/jama.2024.9217", "pmcid": "PMC11337071", "url": "https://pubmed.ncbi.nlm.nih.gov/38819983/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38819983/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID38913535" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT05024032", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "SURMOUNT-CN found weight reduction with tirzepatide in a Chinese population.", "what_it_does_not_show": "The attached erratum was identified but not fully audited; product equivalence remains untested.", "confounders_present": [ "The attached erratum was identified but not fully audited; product equivalence remains untested." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 16, "pmid": "38912654", "title": "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.", "citation": "Malhotra A, Grunstein RR, Fietze I et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. The New England journal of medicine. 2024.", "doi": "10.1056/NEJMoa2404881", "pmcid": "PMC11598664", "url": "https://pubmed.ncbi.nlm.nih.gov/38912654/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38912654/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID39413392" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT05412004", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "SURMOUNT-OSA reduced apnea severity and weight with tirzepatide.", "what_it_does_not_show": "Weight-related mediation and the attached erratum limit a broad mechanism inference; no grey-market arm.", "confounders_present": [ "Weight-related mediation and the attached erratum limit a broad mechanism inference; no grey-market arm." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 17, "pmid": "39536238", "title": "Tirzepatide for Obesity Treatment and Diabetes Prevention.", "citation": "Jastreboff AM, le Roux CW, Stefanski A et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England journal of medicine. 2025.", "doi": "10.1056/NEJMoa2410819", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39536238/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39536238/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SURMOUNT1", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Longer SURMOUNT-1 follow-up supported diabetes prevention in obesity with prediabetes.", "what_it_does_not_show": "This is a later report of the same trial family, not an independent manufacturing or mechanism test.", "confounders_present": [ "This is a later report of the same trial family, not an independent manufacturing or mechanism test." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: SURMOUNT1" ] }, { "n": 18, "pmid": "39555826", "title": "Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.", "citation": "Packer M, Zile MR, Kramer CM et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. The New England journal of medicine. 2025.", "doi": "10.1056/NEJMoa2410027", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39555826/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39555826/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SUMMIT", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "SUMMIT improved the cardiovascular-death/worsening-heart-failure composite and function in obesity with HFpEF.", "what_it_does_not_show": "Composite benefit does not prove a mortality-alone effect or unregulated equivalence.", "confounders_present": [ "Composite benefit does not prove a mortality-alone effect or unregulated equivalence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: SUMMIT" ] }, { "n": 19, "pmid": "37840095", "title": "Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.", "citation": "Wadden TA, Chao AM, Machineni S et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature medicine. 2023.", "doi": "10.1038/s41591-023-02597-w", "pmcid": "PMC10667099", "url": "https://pubmed.ncbi.nlm.nih.gov/37840095/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37840095/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID38409593" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT04657016", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "SURMOUNT-3 improved weight after an intensive lifestyle lead-in.", "what_it_does_not_show": "Lead-in eligibility and an attached erratum restrict interpretation; authentic formulation was tested.", "confounders_present": [ "Lead-in eligibility and an attached erratum restrict interpretation; authentic formulation was tested." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 20, "pmid": "37385275", "title": "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.", "citation": "Garvey WT, Frias JP, Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England). 2023.", "doi": "10.1016/S0140-6736(23)01200-X", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37385275/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37385275/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT04657003", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "SURMOUNT-2 improved weight in obesity with type 2 diabetes.", "what_it_does_not_show": "Diabetic context differs from other populations; sourcing equivalence was not randomized.", "confounders_present": [ "Diabetic context differs from other populations; sourcing equivalence was not randomized." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 21, "pmid": "30473097", "title": "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.", "citation": "Coskun T, Sloop KW, Loghin C et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular metabolism. 2018.", "doi": "10.1016/j.molmet.2018.09.009", "pmcid": "PMC6308032", "url": "https://pubmed.ncbi.nlm.nih.gov/30473097/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30473097/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT02759107", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "LY3298176 preclinical and early clinical studies supported dual receptor effects on metabolic outcomes.", "what_it_does_not_show": "Early phase and mixed receptor action do not prove long-term outcomes or online-product identity.", "confounders_present": [ "Early phase and mixed receptor action do not prove long-term outcomes or online-product identity." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 22, "pmid": "40162940", "title": "Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.", "citation": "Packer M, Zile MR, Kramer CM et al. Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial. Journal of the American College of Cardiology. 2025.", "doi": "10.1016/j.jacc.2025.03.009", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40162940/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40162940/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SUMMIT", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "SUMMIT kidney subgroup analyses reported benefit with differing creatinine and cystatin estimates.", "what_it_does_not_show": "Same trial family; body composition can affect filtration estimates, and subgroup findings do not establish product equivalence.", "confounders_present": [ "Same trial family; body composition can affect filtration estimates, and subgroup findings do not establish product equivalence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: SUMMIT" ] }, { "n": 23, "pmid": "41042549", "title": "RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide.", "citation": "Mashayekhi M, Safa BI, Nian H et al. RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide. The Journal of endocrinology. 2025.", "doi": "10.1530/JOE-25-0174", "pmcid": "PMC12556785", "url": "https://pubmed.ncbi.nlm.nih.gov/41042549/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41042549/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID41042549", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A GLP-1 receptor variant was associated with differing liraglutide responses.", "what_it_does_not_show": "Genotype association is not randomized receptor perturbation or a product comparison.", "confounders_present": [ "Genotype association is not randomized receptor perturbation or a product comparison." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 24, "pmid": "39885064", "title": "A Randomized, Double-Blind, Two-Way Cross-over Study to Evaluate the Efficacy of Liraglutide Treatment in Patients Undergoing Transoral Outlet Reduction Endoscopy for Weight Regain Post Roux-en-Y Gastric Bypass.", "citation": "Lahooti A, Hoff AC, Critelli B et al. A Randomized, Double-Blind, Two-Way Cross-over Study to Evaluate the Efficacy of Liraglutide Treatment in Patients Undergoing Transoral Outlet Reduction Endoscopy for Weight Regain Post Roux-en-Y Gastric Bypass. Obesity surgery. 2025.", "doi": "10.1007/s11695-025-07671-5", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39885064/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39885064/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID39885064", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Liraglutide after an endoscopic bariatric procedure improved weight outcomes under tested timing conditions.", "what_it_does_not_show": "Procedure and timing restrict generalization; no grey-market sourcing comparison.", "confounders_present": [ "Procedure and timing restrict generalization; no grey-market sourcing comparison." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 25, "pmid": "39401933", "title": "A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass.", "citation": "Lofton HF, Maranga G, Hold R et al. A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2025.", "doi": "10.1016/j.soard.2024.08.037", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39401933/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39401933/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID39401933", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Liraglutide supported weight loss after gastric bypass.", "what_it_does_not_show": "Pandemic-related attrition and a postsurgical population limit generality.", "confounders_present": [ "Pandemic-related attrition and a postsurgical population limit generality." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 26, "pmid": "37626125", "title": "A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity.", "citation": "Coppin G, Muñoz Tord D, Pool ER et al. A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity. International journal of obesity (2005). 2023.", "doi": "10.1038/s41366-023-01370-w", "pmcid": "PMC10663148", "url": "https://pubmed.ncbi.nlm.nih.gov/37626125/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37626125/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID37626125", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Liraglutide-induced weight loss occurred without measured changes in food liking in the tested study.", "what_it_does_not_show": "A null selected mediator measure does not rule out all appetite mechanisms or test unregulated products.", "confounders_present": [ "A null selected mediator measure does not rule out all appetite mechanisms or test unregulated products." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 27, "pmid": "35015037", "title": "Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.", "citation": "Rubino DM, Greenway FL, Khalid U et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.", "doi": "10.1001/jama.2021.23619", "pmcid": "PMC8753508", "url": "https://pubmed.ncbi.nlm.nih.gov/35015037/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35015037/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT04074161", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "STEP-8 favored semaglutide over liraglutide for weight loss.", "what_it_does_not_show": "Comparative authentic formulations do not establish equivalence across suppliers.", "confounders_present": [ "Comparative authentic formulations do not establish equivalence across suppliers." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 28, "pmid": "26132939", "title": "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.", "citation": "Pi-Sunyer X, Astrup A, Fujioka K et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. The New England journal of medicine. 2015.", "doi": "10.1056/NEJMoa1411892", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/26132939/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26132939/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT01272219", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "SCALE supported liraglutide-induced weight loss.", "what_it_does_not_show": "This supports licensed intervention efficacy, not research-market efficacy.", "confounders_present": [ "This supports licensed intervention efficacy, not research-market efficacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 29, "pmid": "39258838", "title": "Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.", "citation": "Fox CK, Barrientos-Pérez M, Bomberg EM et al. Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. The New England journal of medicine. 2025.", "doi": "10.1056/NEJMoa2407379", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39258838/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39258838/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT04775082", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Liraglutide reduced BMI in children under the study conditions.", "what_it_does_not_show": "Childhood growth and BMI outcomes cannot be read as universal adult weight loss.", "confounders_present": [ "Childhood growth and BMI outcomes cannot be read as universal adult weight loss." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 30, "pmid": "38785209", "title": "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.", "citation": "Perkovic V, Tuttle KR, Rossing P et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England journal of medicine. 2024.", "doi": "10.1056/NEJMoa2403347", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/38785209/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38785209/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "FLOW", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "FLOW reduced a clinical kidney/cardiovascular composite in type 2 diabetes with CKD.", "what_it_does_not_show": "Disease scope is constrained; no unregulated preparation was assessed.", "confounders_present": [ "Disease scope is constrained; no unregulated preparation was assessed." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: FLOW" ] }, { "n": 31, "pmid": "40162642", "title": "Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.", "citation": "McGuire DK, Marx N, Mulvagh SL et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. The New England journal of medicine. 2025.", "doi": "10.1056/NEJMoa2501006", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40162642/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40162642/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SOUL", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "SOUL reduced major cardiovascular events with oral semaglutide.", "what_it_does_not_show": "Confirmatory secondary endpoints were not all positive; trial formulation is material to the result.", "confounders_present": [ "Confirmatory secondary endpoints were not all positive; trial formulation is material to the result." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: SOUL" ] }, { "n": 32, "pmid": "27633186", "title": "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.", "citation": "Marso SP, Bain SC, Consoli A et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England journal of medicine. 2016.", "doi": "10.1056/NEJMoa1607141", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/27633186/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27633186/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT01720446", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "SUSTAIN-6 supported cardiovascular noninferiority and reported more retinopathy complications.", "what_it_does_not_show": "A benefit signal does not make all clinical outcomes favorable or establish other-product safety.", "confounders_present": [ "A benefit signal does not make all clinical outcomes favorable or establish other-product safety." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 33, "pmid": "38796653", "title": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.", "citation": "Colhoun HM, Lingvay I, Brown PM et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature medicine. 2024.", "doi": "10.1038/s41591-024-03015-5", "pmcid": "PMC11271413", "url": "https://pubmed.ncbi.nlm.nih.gov/38796653/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38796653/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SELECT", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "SELECT kidney analyses reported a secondary kidney benefit.", "what_it_does_not_show": "Same SELECT family; not independent evidence of product identity.", "confounders_present": [ "Same SELECT family; not independent evidence of product identity." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: SELECT" ] }, { "n": 34, "pmid": "31185157", "title": "Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.", "citation": "Husain M, Birkenfeld AL, Donsmark M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England journal of medicine. 2019.", "doi": "10.1056/NEJMoa1901118", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/31185157/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31185157/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT02692716", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "PIONEER-6 established cardiovascular noninferiority for oral semaglutide.", "what_it_does_not_show": "The primary confidence interval did not establish superiority; no unregulated comparator.", "confounders_present": [ "The primary confidence interval did not establish superiority; no unregulated comparator." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 35, "pmid": "38914124", "title": "Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.", "citation": "Mann JFE, Rossing P, Bakris G et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nature medicine. 2024.", "doi": "10.1038/s41591-024-03133-0", "pmcid": "PMC11485243", "url": "https://pubmed.ncbi.nlm.nih.gov/38914124/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38914124/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "FLOW", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "FLOW subgroup analyses assessed outcomes with and without baseline SGLT2 inhibitor use.", "what_it_does_not_show": "Wide subgroup uncertainty and shared parent trial preclude a new independent causal line.", "confounders_present": [ "Wide subgroup uncertainty and shared parent trial preclude a new independent causal line." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: FLOW" ] }, { "n": 36, "pmid": "40156843", "title": "Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.", "citation": "Marx N, Deanfield JE, Mann JFE et al. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation. 2025.", "doi": "10.1161/CIRCULATIONAHA.125.074545", "pmcid": "PMC12144549", "url": "https://pubmed.ncbi.nlm.nih.gov/40156843/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40156843/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SOUL", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "SOUL analyses found broadly consistent cardiovascular results across SGLT2 inhibitor strata.", "what_it_does_not_show": "Same trial family and nonsignificant interaction do not prove identical effects in every stratum.", "confounders_present": [ "Same trial family and nonsignificant interaction do not prove identical effects in every stratum." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: SOUL" ] }, { "n": 37, "pmid": "39217553", "title": "Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.", "citation": "Pratley RE, Tuttle KR, Rossing P et al. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. Journal of the American College of Cardiology. 2024.", "doi": "10.1016/j.jacc.2024.08.004", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39217553/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39217553/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "FLOW", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "FLOW secondary analyses supported heart-failure outcomes.", "what_it_does_not_show": "Shared participants and intervention mean this is not a separate independent line.", "confounders_present": [ "Shared participants and intervention mean this is not a separate independent line." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: FLOW" ] }, { "n": 38, "pmid": "39218393", "title": "A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.", "citation": "Selvarajah V, Robertson D, Hansen L et al. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Kidney international. 2024.", "doi": "10.1016/j.kint.2024.08.023", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39218393/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39218393/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID39218393", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Cotadutide improved albuminuria in a phase 2 kidney-risk study.", "what_it_does_not_show": "A surrogate and mixed receptor intervention do not establish clinical renal benefit or product equivalence.", "confounders_present": [ "A surrogate and mixed receptor intervention do not establish clinical renal benefit or product equivalence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 39, "pmid": "39211948", "title": "Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.", "citation": "Mahaffey KW, Tuttle KR, Arici M et al. Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. European heart journal. 2025.", "doi": "10.1093/eurheartj/ehae613", "pmcid": "PMC11931213", "url": "https://pubmed.ncbi.nlm.nih.gov/39211948/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39211948/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "FLOW", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "FLOW analyses supported cardiovascular consistency across CKD severity.", "what_it_does_not_show": "Same parent trial; subgroup consistency is not universal equivalence.", "confounders_present": [ "Same parent trial; subgroup consistency is not universal equivalence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: FLOW" ] }, { "n": 40, "pmid": "37366315", "title": "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.", "citation": "Jastreboff AM, Kaplan LM, Frías JP et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine. 2023.", "doi": "10.1056/NEJMoa2301972", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37366315/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37366315/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "RETATRUTIDE_PHASE2_OBESITY", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "A phase 2 trial found substantial weight reduction with retatrutide.", "what_it_does_not_show": "Triple receptor action and early-phase authentic product do not validate research-market retatrutide.", "confounders_present": [ "Triple receptor action and early-phase authentic product do not validate research-market retatrutide." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: RETATRUTIDE_PHASE2_OBESITY" ] }, { "n": 41, "pmid": "37385280", "title": "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.", "citation": "Rosenstock J, Frias J, Jastreboff AM et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London, England). 2023.", "doi": "10.1016/S0140-6736(23)01053-X", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37385280/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37385280/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "RETATRUTIDE_PHASE2_T2D", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Retatrutide improved metabolic and weight outcomes in a phase 2 diabetes study.", "what_it_does_not_show": "Selected trial conditions and multiple receptor targets limit a pure GLP-1 mechanism claim.", "confounders_present": [ "Selected trial conditions and multiple receptor targets limit a pure GLP-1 mechanism claim." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: RETATRUTIDE_PHASE2_T2D" ] }, { "n": 42, "pmid": "38858523", "title": "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.", "citation": "Sanyal AJ, Kaplan LM, Frias JP et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine. 2024.", "doi": "10.1038/s41591-024-03018-2", "pmcid": "PMC11271400", "url": "https://pubmed.ncbi.nlm.nih.gov/38858523/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38858523/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "RETATRUTIDE_PHASE2_OBESITY", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Retatrutide reduced liver fat in an obesity-trial substudy.", "what_it_does_not_show": "Surrogate endpoint and shared cohort do not establish liver clinical outcomes or independent replication.", "confounders_present": [ "Surrogate endpoint and shared cohort do not establish liver clinical outcomes or independent replication." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: RETATRUTIDE_PHASE2_OBESITY" ] }, { "n": 43, "pmid": "42250575", "title": "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.", "citation": "Bajaj HS, Welch M, Shah P et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England). 2026.", "doi": "10.1016/S0140-6736(26)00967-0", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/42250575/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42250575/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT06354660", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "TRANSCEND-T2D-1 reported glycemic and weight benefits with retatrutide.", "what_it_does_not_show": "The named trial formulation is not interchangeable with an unverified supplier vial.", "confounders_present": [ "The named trial formulation is not interchangeable with an unverified supplier vial." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 44, "pmid": "40609566", "title": "Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.", "citation": "Coskun T, Wu Q, Schloot NC et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology. 2025.", "doi": "10.1016/S2213-8587(25)00092-0", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40609566/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40609566/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "RETATRUTIDE_PHASE2_T2D", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A retatrutide diabetes-trial substudy measured fat and lean-mass changes.", "what_it_does_not_show": "Shared cohort and body-composition endpoints do not prove net healthspan benefit.", "confounders_present": [ "Shared cohort and body-composition endpoints do not prove net healthspan benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [ "Shared parent randomization/recruitment and outcome ascertainment: RETATRUTIDE_PHASE2_T2D" ] }, { "n": 45, "pmid": "42810372", "title": "Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.", "citation": "Bellido V, le Roux CW, Ekinci EI et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 2026.", "doi": "10.1016/S0140-6736(26)01861-1", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/42810372/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42810372/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT05929079", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "TRIUMPH-2 reported weight benefit with retatrutide in type 2 diabetes.", "what_it_does_not_show": "Regulated trial-product findings do not test unregulated supply chains.", "confounders_present": [ "Regulated trial-product findings do not test unregulated supply chains." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 46, "pmid": "39379664", "title": "Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs.", "citation": "Hach M, Engelund DK, Mysling S et al. Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs. Pharmaceutical research. 2024.", "doi": "10.1007/s11095-024-03771-6", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39379664/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39379664/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID39379664", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Analytical comparison of follow-on GLP-1 products found formulation and impurity differences.", "what_it_does_not_show": "Clinical consequences were not directly measured; tested follow-on products are not a market-wide random sample.", "confounders_present": [ "Clinical consequences were not directly measured; tested follow-on products are not a market-wide random sample." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 47, "pmid": "39776038", "title": "Weight loss and body composition after compounded semaglutide treatment in a real world setting.", "citation": "Chun E, Siojo A, Rivera D et al. Weight loss and body composition after compounded semaglutide treatment in a real world setting. Diabetes, obesity & metabolism. 2025.", "doi": "10.1111/dom.16162", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39776038/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39776038/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID39776038", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "A compounded semaglutide/cyanocobalamin cohort reported weight and body-composition changes.", "what_it_does_not_show": "Uncontrolled combination treatment is neither research-market testing nor a randomized equivalence trial.", "confounders_present": [ "Uncontrolled combination treatment is neither research-market testing nor a randomized equivalence trial." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 48, "pmid": "40418873", "title": "Off-label GLP-1 weight-loss medicine use among online bodybuilders: Folk pharmacology, risk and harm reduction.", "citation": "Turnock LA, Hearne E, Germain J et al. Off-label GLP-1 weight-loss medicine use among online bodybuilders: Folk pharmacology, risk and harm reduction. The International journal on drug policy. 2025.", "doi": "10.1016/j.drugpo.2025.104854", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40418873/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40418873/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID40418873", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Qualitative interviews described online drug-use practices and perceived effects among bodybuilders.", "what_it_does_not_show": "Self-selection, co-use and unverified identity prevent causal efficacy or incidence estimates.", "confounders_present": [ "Self-selection, co-use and unverified identity prevent causal efficacy or incidence estimates." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 49, "pmid": "37392810", "title": "Administration errors of compounded semaglutide reported to a poison control center-Case series.", "citation": "Lambson JE, Flegal SC, Johnson AR. Administration errors of compounded semaglutide reported to a poison control center-Case series. Journal of the American Pharmacists Association : JAPhA. 2023.", "doi": "10.1016/j.japh.2023.06.017", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37392810/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37392810/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID37392810", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Poison-center cases documented adverse events after compounded semaglutide administration errors.", "what_it_does_not_show": "Selected cases cannot measure population risk or separate every formulation problem from administration error.", "confounders_present": [ "Selected cases cannot measure population risk or separate every formulation problem from administration error." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 50, "pmid": "38421490", "title": "Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017-2022.", "citation": "Gaw CE, Hays HL, Kemp CA et al. Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017-2022. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2024.", "doi": "10.1007/s13181-024-00999-x", "pmcid": "PMC10959851", "url": "https://pubmed.ncbi.nlm.nih.gov/38421490/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38421490/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID38421490", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Poison-center surveillance recorded GLP-1 exposures, many involving therapeutic errors.", "what_it_does_not_show": "All GLP-1 exposures are not grey-market exposures, and reported calls are not incidence denominators.", "confounders_present": [ "All GLP-1 exposures are not grey-market exposures, and reported calls are not incidence denominators." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] }, { "n": 51, "pmid": "41125326", "title": "Hypoglycaemic coma induced by a falsified semaglutide product: a case report.", "citation": "Antonacci G, Bortignon E, Bolognesi M et al. Hypoglycaemic coma induced by a falsified semaglutide product: a case report. European journal of hospital pharmacy : science and practice. 2026.", "doi": "10.1136/ejhpharm-2025-004656", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/41125326/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41125326/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID41125326", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "A falsified Ozempic case identified insulin in a product associated with coma.", "what_it_does_not_show": "One counterfeit case establishes a possibility, not the prevalence or efficacy of all research-market products.", "confounders_present": [ "One counterfeit case establishes a possibility, not the prevalence or efficacy of all research-market products." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "shared_components": [] } ], "verification_summary": { "load_bearing_claims_checked": 55, "verified": 55, "unverified": 0, "contradicted": 0, "note": "Verified attribution is distinct from mechanism truth or complete body access." }, "factual_issues_found": [ { "issue": "Abstract compresses two upper-bound endotoxin results into a range; original body qualifiers are retained.", "source": "PMID39509151", "resolution": "No all-positive concentration range or market-wide contamination prevalence is inferred." } ], "cap_rules_applied": [ { "subclaim_id": "SC2", "cap": "Β", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Pure association evidence — however large, however replicated — cannot exceed Β.", "specific_trigger": "Small product assays and adverse-event observations establish measured mismatches, not reliable exposure across an unregulated market. The reliability proposition remains associational and is challenged, rather than causally established.", "resulting_ceiling": "Β" } ], "cap_precedence_resolutions": [ { "collision": "Perturbation in a defined setting versus broader inference", "subclaim_scope_cap_binds_on": "Research-chemical-sourced GLP-1 analogues deliver the efficacy demonstrated in registrational trials.", "subclaim_scope_threshold_binds_on": "The precise experimentally tested subclaim scope", "resolution": "Positive regulated-product clinical effects cross within that tested scope. The broad inference to unregulated supply binds a different claim and cannot inherit Ε. Α for SC3 is a universal narrative assessment, not a claim that an aging-specific cap literally defines manufacturing equivalence.", "note": "Convergent lines are assessed as a set; one weak leg is not re-capped over the assembled case." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID39476339, PMID33567185, PMID38785209", "gamma_hard_rules_triggered": [ "Human associations and biomarker-only changes do not establish the broad causal claim.", "Model perturbations bind their tested species and phenotype, not an untested human scope.", "Positive treatment effects are checked for specific mechanism attribution; negative trials require target engagement before mechanistic falsification." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Randomized authentic products change weight and metabolic trajectories; selected trials also improve clinical kidney, cardiovascular and functional outcomes. Ε is restricted to trial products and tested populations, not arbitrary molecules bearing their names.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "Human associations and biomarker-only changes do not establish the broad causal claim.", "Model perturbations bind their tested species and phenotype, not an untested human scope.", "Positive treatment effects are checked for specific mechanism attribution; negative trials require target engagement before mechanistic falsification." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Small product assays and adverse-event observations establish measured mismatches, not reliable exposure across an unregulated market. The reliability proposition remains associational and is challenged, rather than causally established.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "Human associations and biomarker-only changes do not establish the broad causal claim.", "Model perturbations bind their tested species and phenotype, not an untested human scope.", "Positive treatment effects are checked for specific mechanism attribution; negative trials require target engagement before mechanistic falsification." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "No selected controlled clinical comparison establishes research-chemical product efficacy equivalent to the trial formulations. Transferring a known molecule’s trial efficacy to unverified exposure is a narrative extrapolation.", "ceiling_from_boundary_check": "Γ" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "yes", "supporting_evidence": [ "[8] STEP-9 improved weight, knee pain and function with semaglutide in obesity and knee osteoarthritis.", "[9] STEP-1 demonstrated weight loss with randomized regulated semaglutide.", "[30] FLOW reduced a clinical kidney/cardiovascular composite in type 2 diabetes with CKD." ], "what_would_cross_it": "" }, { "subclaim_id": "SC1", "threshold": "Ε", "requirement_quoted": "Requires causal effect in constrained contexts, backgrounds, or species.", "satisfied": "yes", "supporting_evidence": [ "[8] STEP-9 improved weight, knee pain and function with semaglutide in obesity and knee osteoarthritis.", "[9] STEP-1 demonstrated weight loss with randomized regulated semaglutide.", "[30] FLOW reduced a clinical kidney/cardiovascular composite in type 2 diabetes with CKD." ], "what_would_cross_it": "" }, { "subclaim_id": "SC1", "threshold": "Ζ", "requirement_quoted": "Requires:\n- Reproducible intervention effects\n- Mechanistic narrowing\n- Evidence not reducible to general sickness, caloric reduction, or developmental artifacts", "satisfied": "no", "supporting_evidence": [ "[8] STEP-9 improved weight, knee pain and function with semaglutide in obesity and knee osteoarthritis.", "[9] STEP-1 demonstrated weight loss with randomized regulated semaglutide.", "[30] FLOW reduced a clinical kidney/cardiovascular composite in type 2 diabetes with CKD." ], "what_would_cross_it": "To cross Ζ, establish mechanism-specific independent lines excluding shared pharmacological and product-exposure failures in the stated regulated scope." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Representative blinded batch assays and exposure studies must establish reliable identity, concentration, purity and sterility before outcomes, with denominators and repeat batches." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "A controlled clinical equivalence/noninferiority comparison of independently assayed preparations with exposure verification, prespecified margins and clinical endpoints." } ], "generalization_check": { "generalization_tested": "no", "context_boundary_mapped": "yes", "internal_negative_controls": [ "Withdrawal of authentic product changes weight trajectory but is not a manufacturing control.", "Online-assay failures are selected sample findings, not a complete-market negative control." ], "note": "Regulated studies cover multiple populations, receptor combinations and formulations, but unregulated sourcing is not the tested variable. Compounded, falsified, follow-on and research-market products are kept distinct." }, "falsification_patterns_met": [], "pitfalls_flagged": [ { "pitfall": "Product and scope substitution", "where": "Using registrational trial efficacy as evidence for an unassayed vial." }, { "pitfall": "Reporting denominator error", "where": "Treating spontaneous-report odds or selected poison calls as population incidence." }, { "pitfall": "Analytical interpretation", "where": "Two body endotoxin values are upper bounds; an analytical purity measure is not the measured toxic fraction." } ], "causal_tally_audit": { "tally_claimed_by_document": 31, "tally_after_audit": 31, "items_rejected": [ "Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines.", "The tally counts reports with discriminating intervention contrasts, including negative results; it is not a count of positive causal crossings.", "Shared parent trials and multiple manipulations within a study remain grouped." ] }, "steelman": { "case_one_rung_higher": "Case for Β: licensed products work and selected online samples contain the named peptide. This establishes biological plausibility and some identity observations but not even an adequate controlled outcome association for research-market equivalence.", "case_one_rung_lower": "Α is already the lowest defined rung. Counterfeit or impure products do not justify inventing a lower rung or concluding all unregulated products lack activity.", "which_rejected": "Retain Α for the exact equivalence proposition; preserve Ε for regulated-product causality and Β for measured supply observations.", "blocking_cap_threshold_or_missing_experiment": "Missing experiment: Compare independently assayed candidate preparations against the authentic trial product under ethically authorized product-quality and clinical-trial oversight, with prespecified exposure and clinical equivalence margins; assay every batch before outcomes." }, "final_score": { "hsef_level": "Α", "hsef_descriptor": "Speculative / narrative", "confidence": "Moderate", "confidence_rationale": "51 primary reports with 1 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "Overall Α applies to SC3, the preregistered clinical-equivalence proposition. It does not deny the efficacy of regulated GLP-1 medicines or prove that every research-market preparation is inactive. Product identity, exposure and clinical equivalence cannot be supplied by a chemical label or transferred from a registrational trial." }, "role_of_mechanism": { "classification": "epiphenomenon", "derivation_step_matched": 2, "derivation": "For the nominal research-market equivalence claim, no demonstrated clinical dependency connects this supply category to trial-equivalent outcomes. Step 2 is the framework’s operational classification under unresolved dependency, not proof that the active molecule or every preparation is causally inert. Regulated pharmacology is a different, causally supported subclaim.", "tournament_used_as_tiebreaker": false, "note": "Derived from causal direction, not tournament rank." }, "extended_scoring_MSD": { "momentum": { "value": "Mechanistic only", "artifact": "Recent online-product testing (PMID39509151), analytical comparison (PMID39379664) and adverse-event reports (PMID40285721) examine exposure/quality; no controlled research-market clinical-equivalence experiment was identified.", "justification": "Recent online-product testing (PMID39509151), analytical comparison (PMID39379664) and adverse-event reports (PMID40285721) examine exposure/quality; no controlled research-market clinical-equivalence experiment was identified." }, "stability": { "value": "Stable", "trigger": "No specific pending result with a verified completion trigger was identified in this bounded search; Stable follows the framework definition, not a forecast of permanent truth.", "justification": "No specific pending result with a verified completion trigger was identified in this bounded search; Stable follows the framework definition, not a forecast of permanent truth." }, "divergence": { "implied_level": null, "implied_level_basis": "No single field-implied level is defensible from conflicting framings.", "assessed_level": "Α", "gap_in_rungs": null, "value": "Contested", "justification": "The split is between supplier and user-forum framing, which presents research-chemical preparations as delivering trial-grade results, and the regulatory, analytical and pharmacovigilance literature, which treats their identity and exposure as unverified. No single implied level and no manufactured arithmetic gap applies." }, "calibration_note": "M/S/D never modify HSEF level or confidence." }, "change_record": { "applies": false, "prior_level": "none assigned", "prior_confidence": null, "prior_source": null, "derived_before_consulting_prior": true, "new_level": "Α", "direction": "newly assigned", "what_moved_it": "Fresh primary evidence appraisal; not blinded.", "divergence_from_other_reviewers": null }, "proposed_decisive_experiments": [ { "name": "Registered boundary experiment", "experiment": "Compare independently assayed candidate preparations against the authentic trial product under ethically authorized product-quality and clinical-trial oversight, with prespecified exposure and clinical equivalence margins; assay every batch before outcomes.", "readout": "Verified exposure, prespecified functional/metabolic outcomes and adverse-event ascertainment", "critical_control": "Authentic matched formulation, batch blinding, measured identity/potency/sterility, and identical follow-up", "supporting_result": "Quality and exposure equivalence plus clinical results meeting the registered margins", "falsifying_result": "Mismatched composition/exposure or failure of clinical equivalence despite verified adequate exposure" } ], "knowledge_gaps": [ { "name": "Gap 1", "statement": "Representative repeated-batch testing of research-market products.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 2", "statement": "Controlled clinical equivalence data for verified products.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 3", "statement": "Separation of formulation, administration and identity errors.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 4", "statement": "No market-wide incidence denominator for harm.", "relevance": "Limits mechanism identification or scope." } ], "review_metadata": { "review_date": "2026-10-09", "reviewer": "Codex", "evidence_base_note": "51 primary reports; literature cutoff 2026-10-09; source examination UTC date 2026-10-10; bounded critical review, not exhaustive systematic review.", "literature_tools_available": true, "literature_tools_note": "Life Sciences Literature PubMed/Entrez; separately logged public original-body retrieval; No Consensus or Scite calls used; PubMed primary records and separately logged public original-body retrieval only.", "skill_version": "5.3", "validator_run": "Exact package-bundled v5.3 validator: PASS, zero FAIL findings; rerun after sealing.", "validator_warnings_addressed": "No warnings.", "limits": "Bounded critical review; not systematic review, complete-abstract audit, complete-paper audit, blind calibration or independent peer review.", "consensus_consistency_audit": "2026-10-09; supplementary provenance/source reconciliation; original grading retained; prior grades visible." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "not applicable", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "Ranking categorical verdict and index guidance were visible. No completed blinded calibration claimed." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": false, "why_not_sufficient": "No convergence establishes the full registered claim. Positive narrower results are retained without re-capping an assembled causal set; their scopes and distinct failure modes are stated separately." }, { "kind": "natural_experiment", "available": false, "why_not_sufficient": "No convergence establishes the full registered claim. Positive narrower results are retained without re-capping an assembled causal set; their scopes and distinct failure modes are stated separately." }, { "kind": "dose_response_across_populations", "available": false, "why_not_sufficient": "No convergence establishes the full registered claim. Positive narrower results are retained without re-capping an assembled causal set; their scopes and distinct failure modes are stated separately." }, { "kind": "withdrawal_rechallenge", "available": false, "why_not_sufficient": "No convergence establishes the full registered claim. Positive narrower results are retained without re-capping an assembled causal set; their scopes and distinct failure modes are stated separately." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": false, "why_not_sufficient": "No convergence establishes the full registered claim. Positive narrower results are retained without re-capping an assembled causal set; their scopes and distinct failure modes are stated separately." } ], "convergence_present": false, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 51, "claims_total": 55, "claims_verified": 55, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 51, "generated_by": "Codex; HSEF v5.3", "gate_passed": true }, "claims": [ { "id": "C1", "text": "Purchased online semaglutide samples contained the named peptide but had analytical and label mismatches. Three delivered samples cannot estimate market-wide reliability; purity measurements do not identify the toxicity of every impurity. Two endotoxin results in the body are upper bounds, not quantified concentrations.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:Results:paragraph15, 2:Results:paragraph27, 2:Results:paragraph28, 2:Results:paragraph32. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C2", "text": "Compounded GLP-1 adverse-event reports disproportionately included quality and administration problems. Spontaneous reporting odds are not incidence; compounded and research-market products are different categories.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C3", "text": "Prescribed semaglutide was associated with weight loss in clinical practice. An observational prescription cohort does not test unregulated products or eliminate attrition bias.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C4", "text": "A matched prescription cohort associated tirzepatide with greater weight loss than semaglutide. Residual confounding and treatment discontinuation remain; neither product was an unregulated comparator.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C5", "text": "SELECT randomized semaglutide reduced cardiovascular events in obesity with prior cardiovascular disease. This is regulated-product efficacy in a selected high-risk population, not identity or bioequivalence of online vials.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C6", "text": "SURMOUNT-5 randomized comparison favored tirzepatide over semaglutide for weight loss. Open-label comparison and dual receptor pharmacology do not establish equivalence of research-sourced molecules.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C7", "text": "OASIS-4 found weight reduction with the tested oral semaglutide formulation. Formulation-specific trial results cannot establish absorption or efficacy of a different product.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C8", "text": "STEP-9 improved weight, knee pain and function with semaglutide in obesity and knee osteoarthritis. Weight mediation and the selected clinical context remain; unregulated sourcing was not tested.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C9", "text": "STEP-1 demonstrated weight loss with randomized regulated semaglutide. Authentic trial-product exposure is the controlled variable; a supplier's chemical name alone is not that exposure.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C10", "text": "STEP-TEENS reduced BMI with semaglutide in adolescents. Developmental context and BMI endpoints differ from adult outcomes; no online-product comparison.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C11", "text": "STEP-5 showed sustained weight loss over two years with semaglutide. Sustained trial efficacy does not establish batch consistency elsewhere.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C12", "text": "STEP-4 continuation maintained weight loss whereas withdrawal led to regain. The randomized population completed a tolerability run-in; withdrawal of an authentic product is not a supply-chain test.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C13", "text": "SURMOUNT-1 demonstrated weight reduction with tirzepatide. Dual GIP/GLP-1 action and regulated manufacture cannot be assigned to an unassayed vial.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C14", "text": "SURMOUNT-4 continuation and withdrawal separated weight trajectories. Run-in selection restricts generality; the trial does not establish unregulated equivalence.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C15", "text": "SURMOUNT-CN found weight reduction with tirzepatide in a Chinese population. The attached erratum was identified but not fully audited; product equivalence remains untested.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C16", "text": "SURMOUNT-OSA reduced apnea severity and weight with tirzepatide. Weight-related mediation and the attached erratum limit a broad mechanism inference; no grey-market arm.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C17", "text": "Longer SURMOUNT-1 follow-up supported diabetes prevention in obesity with prediabetes. This is a later report of the same trial family, not an independent manufacturing or mechanism test.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C18", "text": "SUMMIT improved the cardiovascular-death/worsening-heart-failure composite and function in obesity with HFpEF. Composite benefit does not prove a mortality-alone effect or unregulated equivalence.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C19", "text": "SURMOUNT-3 improved weight after an intensive lifestyle lead-in. Lead-in eligibility and an attached erratum restrict interpretation; authentic formulation was tested.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C20", "text": "SURMOUNT-2 improved weight in obesity with type 2 diabetes. Diabetic context differs from other populations; sourcing equivalence was not randomized.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C21", "text": "LY3298176 preclinical and early clinical studies supported dual receptor effects on metabolic outcomes. Early phase and mixed receptor action do not prove long-term outcomes or online-product identity.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C22", "text": "SUMMIT kidney subgroup analyses reported benefit with differing creatinine and cystatin estimates. Same trial family; body composition can affect filtration estimates, and subgroup findings do not establish product equivalence.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C23", "text": "A GLP-1 receptor variant was associated with differing liraglutide responses. Genotype association is not randomized receptor perturbation or a product comparison.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C24", "text": "Liraglutide after an endoscopic bariatric procedure improved weight outcomes under tested timing conditions. Procedure and timing restrict generalization; no grey-market sourcing comparison.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C25", "text": "Liraglutide supported weight loss after gastric bypass. Pandemic-related attrition and a postsurgical population limit generality.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C26", "text": "Liraglutide-induced weight loss occurred without measured changes in food liking in the tested study. A null selected mediator measure does not rule out all appetite mechanisms or test unregulated products.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C27", "text": "STEP-8 favored semaglutide over liraglutide for weight loss. Comparative authentic formulations do not establish equivalence across suppliers.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 27 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C28", "text": "SCALE supported liraglutide-induced weight loss. This supports licensed intervention efficacy, not research-market efficacy.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 28 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C29", "text": "Liraglutide reduced BMI in children under the study conditions. Childhood growth and BMI outcomes cannot be read as universal adult weight loss.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 29 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C30", "text": "FLOW reduced a clinical kidney/cardiovascular composite in type 2 diabetes with CKD. Disease scope is constrained; no unregulated preparation was assessed.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 30 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C31", "text": "SOUL reduced major cardiovascular events with oral semaglutide. Confirmatory secondary endpoints were not all positive; trial formulation is material to the result.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 31 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C32", "text": "SUSTAIN-6 supported cardiovascular noninferiority and reported more retinopathy complications. A benefit signal does not make all clinical outcomes favorable or establish other-product safety.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 32 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C33", "text": "SELECT kidney analyses reported a secondary kidney benefit. Same SELECT family; not independent evidence of product identity.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 33 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C34", "text": "PIONEER-6 established cardiovascular noninferiority for oral semaglutide. The primary confidence interval did not establish superiority; no unregulated comparator.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 34 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C35", "text": "FLOW subgroup analyses assessed outcomes with and without baseline SGLT2 inhibitor use. Wide subgroup uncertainty and shared parent trial preclude a new independent causal line.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 35 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C36", "text": "SOUL analyses found broadly consistent cardiovascular results across SGLT2 inhibitor strata. Same trial family and nonsignificant interaction do not prove identical effects in every stratum.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 36 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C37", "text": "FLOW secondary analyses supported heart-failure outcomes. Shared participants and intervention mean this is not a separate independent line.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 37 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C38", "text": "Cotadutide improved albuminuria in a phase 2 kidney-risk study. A surrogate and mixed receptor intervention do not establish clinical renal benefit or product equivalence.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 38 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C39", "text": "FLOW analyses supported cardiovascular consistency across CKD severity. Same parent trial; subgroup consistency is not universal equivalence.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 39 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C40", "text": "A phase 2 trial found substantial weight reduction with retatrutide. Triple receptor action and early-phase authentic product do not validate research-market retatrutide.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 40 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C41", "text": "Retatrutide improved metabolic and weight outcomes in a phase 2 diabetes study. Selected trial conditions and multiple receptor targets limit a pure GLP-1 mechanism claim.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 41 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C42", "text": "Retatrutide reduced liver fat in an obesity-trial substudy. Surrogate endpoint and shared cohort do not establish liver clinical outcomes or independent replication.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 42 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C43", "text": "TRANSCEND-T2D-1 reported glycemic and weight benefits with retatrutide. The named trial formulation is not interchangeable with an unverified supplier vial.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 43 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C44", "text": "A retatrutide diabetes-trial substudy measured fat and lean-mass changes. Shared cohort and body-composition endpoints do not prove net healthspan benefit.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 44 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C45", "text": "TRIUMPH-2 reported weight benefit with retatrutide in type 2 diabetes. Regulated trial-product findings do not test unregulated supply chains.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 45 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C46", "text": "Analytical comparison of follow-on GLP-1 products found formulation and impurity differences. Clinical consequences were not directly measured; tested follow-on products are not a market-wide random sample.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 46 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C47", "text": "A compounded semaglutide/cyanocobalamin cohort reported weight and body-composition changes. Uncontrolled combination treatment is neither research-market testing nor a randomized equivalence trial.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 47 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C48", "text": "Qualitative interviews described online drug-use practices and perceived effects among bodybuilders. Self-selection, co-use and unverified identity prevent causal efficacy or incidence estimates.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 48 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C49", "text": "Poison-center cases documented adverse events after compounded semaglutide administration errors. Selected cases cannot measure population risk or separate every formulation problem from administration error.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 49 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C50", "text": "Poison-center surveillance recorded GLP-1 exposures, many involving therapeutic errors. All GLP-1 exposures are not grey-market exposures, and reported calls are not incidence denominators.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 50 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "C51", "text": "A falsified Ozempic case identified insulin in a product associated with coma. One counterfeit case establishes a possibility, not the prevalence or efficacy of all research-market products.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 51 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-10", "note": "" }, { "id": "CSC1", "text": "Randomized authentic products change weight and metabolic trajectories; selected trials also improve clinical kidney, cardiovascular and functional outcomes. Ε is restricted to trial products and tested populations, not arbitrary molecules bearing their names.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-10", "note": "" }, { "id": "CSC2", "text": "Small product assays and adverse-event observations establish measured mismatches, not reliable exposure across an unregulated market. The reliability proposition remains associational and is challenged, rather than causally established.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 1, 2, 46, 47, 48, 49, 50, 51 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-10", "note": "" }, { "id": "CSC3", "text": "No selected controlled clinical comparison establishes research-chemical product efficacy equivalent to the trial formulations. Transferring a known molecule’s trial efficacy to unverified exposure is a narrative extrapolation.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 1, 2, 46, 47, 48, 49, 50, 51 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-10", "note": "" }, { "id": "CH", "text": "Regulated GLP-1 medicines have causal clinical evidence; equivalent efficacy of unregulated research-chemical products has not been established.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 9, 30, 1, 46 ], "verification": "verified", "verified_against": "Bounded synthesis of examined sources; score is adjudication.", "verified_on": "2026-10-10", "note": "" } ], "citation_ledger": [ { "n": 1, "citation": "Ashraf AR, Mackey TK, Vida RG et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of medical Internet research. 2024.", "tier": "A", "kind": "primary", "pmid": "39509151", "doi": "10.2196/65440", "url": "https://pubmed.ncbi.nlm.nih.gov/39509151/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID39509151", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:Results:paragraph15, 2:Results:paragraph27, 2:Results:paragraph28, 2:Results:paragraph32. No complete-paper or supplement audit claimed.", "carries_claims": [ "C1", "CSC2", "CSC3", "CH" ] }, { "n": 2, "citation": "McCall KL, Mastro Dwyer KA, Casey RT et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert opinion on drug safety. 2026.", "tier": "A", "kind": "primary", "pmid": "40285721", "doi": "10.1080/14740338.2025.2499670", "url": "https://pubmed.ncbi.nlm.nih.gov/40285721/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID40285721", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C2", "CSC2", "CSC3" ] }, { "n": 3, "citation": "Alabduljabbar K, Alsaqaaby M, Neff KJ et al. Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting. Endocrine. 2024.", "tier": "A", "kind": "primary", "pmid": "37735340", "doi": "10.1007/s12020-023-03534-0", "url": "https://pubmed.ncbi.nlm.nih.gov/37735340/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID37735340", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C3", "CSC1" ] }, { "n": 4, "citation": "Rodriguez PJ, Goodwin Cartwright BM, Gratzl S et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA internal medicine. 2024.", "tier": "A", "kind": "primary", "pmid": "38976257", "doi": "10.1001/jamainternmed.2024.2525", "url": "https://pubmed.ncbi.nlm.nih.gov/38976257/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID38976257", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C4", "CSC1" ] }, { "n": 5, "citation": "Lincoff AM, Brown-Frandsen K, Colhoun HM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England journal of medicine. 2023.", "tier": "A", "kind": "rct", "pmid": "37952131", "doi": "10.1056/NEJMoa2307563", "url": "https://pubmed.ncbi.nlm.nih.gov/37952131/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SELECT", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C5", "CSC1" ] }, { "n": 6, "citation": "Aronne LJ, Horn DB, le Roux CW et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. The New England journal of medicine. 2025.", "tier": "A", "kind": "primary", "pmid": "40353578", "doi": "10.1056/NEJMoa2416394", "url": "https://pubmed.ncbi.nlm.nih.gov/40353578/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT05822830", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C6", "CSC1" ] }, { "n": 7, "citation": "Wharton S, Lingvay I, Bogdanski P et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. The New England journal of medicine. 2025.", "tier": "A", "kind": "rct", "pmid": "40934115", "doi": "10.1056/NEJMoa2500969", "url": "https://pubmed.ncbi.nlm.nih.gov/40934115/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT05564117", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C7", "CSC1" ] }, { "n": 8, "citation": "Bliddal H, Bays H, Czernichow S et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England journal of medicine. 2024.", "tier": "A", "kind": "rct", "pmid": "39476339", "doi": "10.1056/NEJMoa2403664", "url": "https://pubmed.ncbi.nlm.nih.gov/39476339/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT05064735", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C8", "CSC1" ] }, { "n": 9, "citation": "Wilding JPH, Batterham RL, Calanna S et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. 2021.", "tier": "A", "kind": "rct", "pmid": "33567185", "doi": "10.1056/NEJMoa2032183", "url": "https://pubmed.ncbi.nlm.nih.gov/33567185/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT03548935", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C9", "CSC1", "CH" ] }, { "n": 10, "citation": "Weghuber D, Barrett T, Barrientos-Pérez M et al. Once-Weekly Semaglutide in Adolescents with Obesity. The New England journal of medicine. 2022.", "tier": "A", "kind": "rct", "pmid": "36322838", "doi": "10.1056/NEJMoa2208601", "url": "https://pubmed.ncbi.nlm.nih.gov/36322838/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT04102189", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C10", "CSC1" ] }, { "n": 11, "citation": "Garvey WT, Batterham RL, Bhatta M et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature medicine. 2022.", "tier": "A", "kind": "rct", "pmid": "36216945", "doi": "10.1038/s41591-022-02026-4", "url": "https://pubmed.ncbi.nlm.nih.gov/36216945/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT03693430", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C11", "CSC1" ] }, { "n": 12, "citation": "Rubino D, Abrahamsson N, Davies M et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.", "tier": "A", "kind": "rct", "pmid": "33755728", "doi": "10.1001/jama.2021.3224", "url": "https://pubmed.ncbi.nlm.nih.gov/33755728/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT03548987", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C12", "CSC1" ] }, { "n": 13, "citation": "Jastreboff AM, Aronne LJ, Ahmad NN et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine. 2022.", "tier": "A", "kind": "rct", "pmid": "35658024", "doi": "10.1056/NEJMoa2206038", "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SURMOUNT1", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C13", "CSC1" ] }, { "n": 14, "citation": "Aronne LJ, Sattar N, Horn DB et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.", "tier": "A", "kind": "rct", "pmid": "38078870", "doi": "10.1001/jama.2023.24945", "url": "https://pubmed.ncbi.nlm.nih.gov/38078870/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT04660643", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C14", "CSC1" ] }, { "n": 15, "citation": "Zhao L, Cheng Z, Lu Y et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024.", "tier": "A", "kind": "rct", "pmid": "38819983", "doi": "10.1001/jama.2024.9217", "url": "https://pubmed.ncbi.nlm.nih.gov/38819983/", "status_flags": [ "ErratumIn: PMID38913535" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT05024032", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C15", "CSC1" ] }, { "n": 16, "citation": "Malhotra A, Grunstein RR, Fietze I et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. The New England journal of medicine. 2024.", "tier": "A", "kind": "rct", "pmid": "38912654", "doi": "10.1056/NEJMoa2404881", "url": "https://pubmed.ncbi.nlm.nih.gov/38912654/", "status_flags": [ "ErratumIn: PMID39413392" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT05412004", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C16", "CSC1" ] }, { "n": 17, "citation": "Jastreboff AM, le Roux CW, Stefanski A et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England journal of medicine. 2025.", "tier": "A", "kind": "rct", "pmid": "39536238", "doi": "10.1056/NEJMoa2410819", "url": "https://pubmed.ncbi.nlm.nih.gov/39536238/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SURMOUNT1", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C17", "CSC1" ] }, { "n": 18, "citation": "Packer M, Zile MR, Kramer CM et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. The New England journal of medicine. 2025.", "tier": "A", "kind": "rct", "pmid": "39555826", "doi": "10.1056/NEJMoa2410027", "url": "https://pubmed.ncbi.nlm.nih.gov/39555826/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SUMMIT", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C18", "CSC1" ] }, { "n": 19, "citation": "Wadden TA, Chao AM, Machineni S et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature medicine. 2023.", "tier": "A", "kind": "rct", "pmid": "37840095", "doi": "10.1038/s41591-023-02597-w", "url": "https://pubmed.ncbi.nlm.nih.gov/37840095/", "status_flags": [ "ErratumIn: PMID38409593" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT04657016", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C19", "CSC1" ] }, { "n": 20, "citation": "Garvey WT, Frias JP, Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England). 2023.", "tier": "A", "kind": "rct", "pmid": "37385275", "doi": "10.1016/S0140-6736(23)01200-X", "url": "https://pubmed.ncbi.nlm.nih.gov/37385275/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT04657003", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C20", "CSC1" ] }, { "n": 21, "citation": "Coskun T, Sloop KW, Loghin C et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular metabolism. 2018.", "tier": "A", "kind": "rct", "pmid": "30473097", "doi": "10.1016/j.molmet.2018.09.009", "url": "https://pubmed.ncbi.nlm.nih.gov/30473097/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT02759107", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C21", "CSC1" ] }, { "n": 22, "citation": "Packer M, Zile MR, Kramer CM et al. Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial. Journal of the American College of Cardiology. 2025.", "tier": "A", "kind": "rct", "pmid": "40162940", "doi": "10.1016/j.jacc.2025.03.009", "url": "https://pubmed.ncbi.nlm.nih.gov/40162940/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SUMMIT", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C22", "CSC1" ] }, { "n": 23, "citation": "Mashayekhi M, Safa BI, Nian H et al. RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide. The Journal of endocrinology. 2025.", "tier": "A", "kind": "rct", "pmid": "41042549", "doi": "10.1530/JOE-25-0174", "url": "https://pubmed.ncbi.nlm.nih.gov/41042549/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID41042549", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C23", "CSC1" ] }, { "n": 24, "citation": "Lahooti A, Hoff AC, Critelli B et al. A Randomized, Double-Blind, Two-Way Cross-over Study to Evaluate the Efficacy of Liraglutide Treatment in Patients Undergoing Transoral Outlet Reduction Endoscopy for Weight Regain Post Roux-en-Y Gastric Bypass. Obesity surgery. 2025.", "tier": "A", "kind": "rct", "pmid": "39885064", "doi": "10.1007/s11695-025-07671-5", "url": "https://pubmed.ncbi.nlm.nih.gov/39885064/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID39885064", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C24", "CSC1" ] }, { "n": 25, "citation": "Lofton HF, Maranga G, Hold R et al. A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2025.", "tier": "A", "kind": "rct", "pmid": "39401933", "doi": "10.1016/j.soard.2024.08.037", "url": "https://pubmed.ncbi.nlm.nih.gov/39401933/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID39401933", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C25", "CSC1" ] }, { "n": 26, "citation": "Coppin G, Muñoz Tord D, Pool ER et al. A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity. International journal of obesity (2005). 2023.", "tier": "A", "kind": "rct", "pmid": "37626125", "doi": "10.1038/s41366-023-01370-w", "url": "https://pubmed.ncbi.nlm.nih.gov/37626125/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID37626125", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C26", "CSC1" ] }, { "n": 27, "citation": "Rubino DM, Greenway FL, Khalid U et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.", "tier": "A", "kind": "rct", "pmid": "35015037", "doi": "10.1001/jama.2021.23619", "url": "https://pubmed.ncbi.nlm.nih.gov/35015037/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT04074161", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C27", "CSC1" ] }, { "n": 28, "citation": "Pi-Sunyer X, Astrup A, Fujioka K et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. The New England journal of medicine. 2015.", "tier": "A", "kind": "rct", "pmid": "26132939", "doi": "10.1056/NEJMoa1411892", "url": "https://pubmed.ncbi.nlm.nih.gov/26132939/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT01272219", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C28", "CSC1" ] }, { "n": 29, "citation": "Fox CK, Barrientos-Pérez M, Bomberg EM et al. Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. The New England journal of medicine. 2025.", "tier": "A", "kind": "rct", "pmid": "39258838", "doi": "10.1056/NEJMoa2407379", "url": "https://pubmed.ncbi.nlm.nih.gov/39258838/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT04775082", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C29", "CSC1" ] }, { "n": 30, "citation": "Perkovic V, Tuttle KR, Rossing P et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England journal of medicine. 2024.", "tier": "A", "kind": "rct", "pmid": "38785209", "doi": "10.1056/NEJMoa2403347", "url": "https://pubmed.ncbi.nlm.nih.gov/38785209/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "FLOW", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C30", "CSC1", "CH" ] }, { "n": 31, "citation": "McGuire DK, Marx N, Mulvagh SL et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. The New England journal of medicine. 2025.", "tier": "A", "kind": "rct", "pmid": "40162642", "doi": "10.1056/NEJMoa2501006", "url": "https://pubmed.ncbi.nlm.nih.gov/40162642/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SOUL", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C31", "CSC1" ] }, { "n": 32, "citation": "Marso SP, Bain SC, Consoli A et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England journal of medicine. 2016.", "tier": "A", "kind": "rct", "pmid": "27633186", "doi": "10.1056/NEJMoa1607141", "url": "https://pubmed.ncbi.nlm.nih.gov/27633186/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT01720446", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C32", "CSC1" ] }, { "n": 33, "citation": "Colhoun HM, Lingvay I, Brown PM et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature medicine. 2024.", "tier": "A", "kind": "rct", "pmid": "38796653", "doi": "10.1038/s41591-024-03015-5", "url": "https://pubmed.ncbi.nlm.nih.gov/38796653/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SELECT", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C33", "CSC1" ] }, { "n": 34, "citation": "Husain M, Birkenfeld AL, Donsmark M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England journal of medicine. 2019.", "tier": "A", "kind": "rct", "pmid": "31185157", "doi": "10.1056/NEJMoa1901118", "url": "https://pubmed.ncbi.nlm.nih.gov/31185157/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT02692716", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C34", "CSC1" ] }, { "n": 35, "citation": "Mann JFE, Rossing P, Bakris G et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nature medicine. 2024.", "tier": "A", "kind": "rct", "pmid": "38914124", "doi": "10.1038/s41591-024-03133-0", "url": "https://pubmed.ncbi.nlm.nih.gov/38914124/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "FLOW", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C35", "CSC1" ] }, { "n": 36, "citation": "Marx N, Deanfield JE, Mann JFE et al. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation. 2025.", "tier": "A", "kind": "rct", "pmid": "40156843", "doi": "10.1161/CIRCULATIONAHA.125.074545", "url": "https://pubmed.ncbi.nlm.nih.gov/40156843/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "SOUL", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C36", "CSC1" ] }, { "n": 37, "citation": "Pratley RE, Tuttle KR, Rossing P et al. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. Journal of the American College of Cardiology. 2024.", "tier": "A", "kind": "rct", "pmid": "39217553", "doi": "10.1016/j.jacc.2024.08.004", "url": "https://pubmed.ncbi.nlm.nih.gov/39217553/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "FLOW", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C37", "CSC1" ] }, { "n": 38, "citation": "Selvarajah V, Robertson D, Hansen L et al. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Kidney international. 2024.", "tier": "A", "kind": "rct", "pmid": "39218393", "doi": "10.1016/j.kint.2024.08.023", "url": "https://pubmed.ncbi.nlm.nih.gov/39218393/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID39218393", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C38", "CSC1" ] }, { "n": 39, "citation": "Mahaffey KW, Tuttle KR, Arici M et al. Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. European heart journal. 2025.", "tier": "A", "kind": "rct", "pmid": "39211948", "doi": "10.1093/eurheartj/ehae613", "url": "https://pubmed.ncbi.nlm.nih.gov/39211948/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "FLOW", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C39", "CSC1" ] }, { "n": 40, "citation": "Jastreboff AM, Kaplan LM, Frías JP et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine. 2023.", "tier": "A", "kind": "rct", "pmid": "37366315", "doi": "10.1056/NEJMoa2301972", "url": "https://pubmed.ncbi.nlm.nih.gov/37366315/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "RETATRUTIDE_PHASE2_OBESITY", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C40", "CSC1" ] }, { "n": 41, "citation": "Rosenstock J, Frias J, Jastreboff AM et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London, England). 2023.", "tier": "A", "kind": "rct", "pmid": "37385280", "doi": "10.1016/S0140-6736(23)01053-X", "url": "https://pubmed.ncbi.nlm.nih.gov/37385280/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "RETATRUTIDE_PHASE2_T2D", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C41", "CSC1" ] }, { "n": 42, "citation": "Sanyal AJ, Kaplan LM, Frias JP et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine. 2024.", "tier": "A", "kind": "rct", "pmid": "38858523", "doi": "10.1038/s41591-024-03018-2", "url": "https://pubmed.ncbi.nlm.nih.gov/38858523/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "RETATRUTIDE_PHASE2_OBESITY", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C42", "CSC1" ] }, { "n": 43, "citation": "Bajaj HS, Welch M, Shah P et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet (London, England). 2026.", "tier": "A", "kind": "rct", "pmid": "42250575", "doi": "10.1016/S0140-6736(26)00967-0", "url": "https://pubmed.ncbi.nlm.nih.gov/42250575/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT06354660", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C43", "CSC1" ] }, { "n": 44, "citation": "Coskun T, Wu Q, Schloot NC et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The lancet. Diabetes & endocrinology. 2025.", "tier": "A", "kind": "rct", "pmid": "40609566", "doi": "10.1016/S2213-8587(25)00092-0", "url": "https://pubmed.ncbi.nlm.nih.gov/40609566/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "RETATRUTIDE_PHASE2_T2D", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C44", "CSC1" ] }, { "n": 45, "citation": "Bellido V, le Roux CW, Ekinci EI et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 2026.", "tier": "A", "kind": "rct", "pmid": "42810372", "doi": "10.1016/S0140-6736(26)01861-1", "url": "https://pubmed.ncbi.nlm.nih.gov/42810372/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "NCT05929079", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C45", "CSC1" ] }, { "n": 46, "citation": "Hach M, Engelund DK, Mysling S et al. Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs. Pharmaceutical research. 2024.", "tier": "A", "kind": "primary", "pmid": "39379664", "doi": "10.1007/s11095-024-03771-6", "url": "https://pubmed.ncbi.nlm.nih.gov/39379664/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID39379664", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C46", "CSC2", "CSC3", "CH" ] }, { "n": 47, "citation": "Chun E, Siojo A, Rivera D et al. Weight loss and body composition after compounded semaglutide treatment in a real world setting. Diabetes, obesity & metabolism. 2025.", "tier": "A", "kind": "primary", "pmid": "39776038", "doi": "10.1111/dom.16162", "url": "https://pubmed.ncbi.nlm.nih.gov/39776038/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID39776038", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C47", "CSC2", "CSC3" ] }, { "n": 48, "citation": "Turnock LA, Hearne E, Germain J et al. Off-label GLP-1 weight-loss medicine use among online bodybuilders: Folk pharmacology, risk and harm reduction. The International journal on drug policy. 2025.", "tier": "A", "kind": "primary", "pmid": "40418873", "doi": "10.1016/j.drugpo.2025.104854", "url": "https://pubmed.ncbi.nlm.nih.gov/40418873/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID40418873", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C48", "CSC2", "CSC3" ] }, { "n": 49, "citation": "Lambson JE, Flegal SC, Johnson AR. Administration errors of compounded semaglutide reported to a poison control center-Case series. Journal of the American Pharmacists Association : JAPhA. 2023.", "tier": "A", "kind": "primary", "pmid": "37392810", "doi": "10.1016/j.japh.2023.06.017", "url": "https://pubmed.ncbi.nlm.nih.gov/37392810/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID37392810", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C49", "CSC2", "CSC3" ] }, { "n": 50, "citation": "Gaw CE, Hays HL, Kemp CA et al. Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017-2022. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2024.", "tier": "A", "kind": "primary", "pmid": "38421490", "doi": "10.1007/s13181-024-00999-x", "url": "https://pubmed.ncbi.nlm.nih.gov/38421490/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID38421490", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C50", "CSC2", "CSC3" ] }, { "n": 51, "citation": "Antonacci G, Bortignon E, Bolognesi M et al. Hypoglycaemic coma induced by a falsified semaglutide product: a case report. European journal of hospital pharmacy : science and practice. 2026.", "tier": "A", "kind": "primary", "pmid": "41125326", "doi": "10.1136/ejhpharm-2025-004656", "url": "https://pubmed.ncbi.nlm.nih.gov/41125326/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-10", "status_checked_on": "2026-10-10", "study_id": "PMID41125326", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C51", "CSC2", "CSC3" ] } ], "independence_basis": { "required": false, "lines": [], "shared_failure_mode_checked": true, "note": "Different publications, laboratories and agents do not automatically form independent causal lines. No nominal Ζ or higher is assigned." }, "consensus_validation": { "score_after": { "hsef_level": "Α", "hsef_descriptor": "Speculative / narrative", "confidence": "Moderate", "confidence_rationale": "51 primary reports with 1 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "Overall Α applies to SC3, the preregistered clinical-equivalence proposition. It does not deny the efficacy of regulated GLP-1 medicines or prove that every research-market preparation is inactive. Product identity, exposure and clinical equivalence cannot be supplied by a chemical label or transferred from a registrational trial." }, "primary_comparisons": [ { "doi": "10.2196/65440", "study_group": "PMID39509151", "access_depth": "Original primary abstract plus selected full-text body passages; already in frozen ledger source 1", "pmid": "39509151", "result_comparison": "Three delivered products from six purchase attempts were substandard/falsified; low purity, excess measured content and reported endotoxin. Agrees directionally with provider answer, but small selected sample does not justify prevalence/frequency language." }, { "doi": "10.1136/ejhpharm-2025-004656", "study_group": "PMID41125326", "access_depth": "Original primary PubMed abstract; already in frozen ledger source 51", "pmid": "41125326", "result_comparison": "Single confirmed online-sourced falsified product contained insulin; supports a documented hazard, not market frequency." }, { "doi": "10.3389/fphar.2026.1805842", "study_group": "EudraVigilance ICSR dataset 2018-2025", "access_depth": "Original primary PubMed abstract; absent from frozen 51-source ledger, supplemental", "pmid": "42137313", "result_comparison": "234 potential-counterfeit ICSRs and reporting-disproportionality signals; no denominator or confirmed authentication, so not incidence/causality." }, { "doi": "10.1007/s11095-024-03771-6", "study_group": "PMID39379664", "access_depth": "Original primary abstract; already in frozen ledger", "pmid": "39379664", "result_comparison": "Follow-on-product assay supports formulation/impurity variability; distinct category from illicit research-chemical products, no clinical consequence established." }, { "pmid": "42533250", "doi": "10.1007/s11095-026-04146-9", "source_type": "primary in-vitro study; supplemental, outside frozen ledger", "access_depth": "Consensus fetch record saved verbatim; bibliographic publication-year metadata and PubMed record checked; abstract-level primary findings", "study_group": "follow-on and compounded GLP-1 product samples, in-vitro assay", "result_comparison": "Different impurities and in-vitro immunogenic peptide presentation versus originators; does not test grey-market online products or clinical immunogenicity/safety; author conflicts include Novo Nordisk employees/shareholders." } ], "grade_changed": false, "raw_paths": [ "consensus-browser-response.md", "browser-thread.json", "consensus-search-raw.json", "consensus-fetch-76090d1d936b5dc3bd8a635ced882462.json" ], "queries": [ "grey-market semaglutide quality source verification (browser request in browser-thread.json)", "semaglutide online research products purity identity contamination analysis compounded products 2023 2025" ], "cutoff": "2026-10-09", "score_before": { "hsef_level": "Α", "hsef_descriptor": "Speculative / narrative", "confidence": "Moderate", "confidence_rationale": "51 primary reports with 1 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "Overall Α applies to SC3, the preregistered clinical-equivalence proposition. It does not deny the efficacy of regulated GLP-1 medicines or prove that every research-market preparation is inactive. Product identity, exposure and clinical equivalence cannot be supplied by a chemical label or transferred from a registrational trial." }, "conclusion": "No direct clinical efficacy equivalence comparison found. Supplementary pharmacovigilance adds a signal but does not change the preregistered SC3 conclusion or score.", "addendum_path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\grey-market-glp1\\addendum.md", "original_counts_preserved": { "claims_total": 55, "sources_total": 51 }, "completed": true, "independent_blinded_audit": false, "provider_mode": "Consensus Pro browser thread plus Consensus keyword search/fetch", "source_id_reconciliation": [ { "study_group": "PMID39509151", "status": "present", "id": "PMID 39509151 / DOI 10.2196/65440", "location": "selected-records.json, evidence.json, review, appraisals.tsv; source 1" }, { "study_group": "same product-purchase family, pending methods-level overlap determination", "status": "absent from selected-records.json", "id": "DOI 10.1001/jamanetworkopen.2024.28280", "location": "Consensus-cited related Ashraf/Mackey research letter; likely same online-purchase family, not an independent sample based on source description" }, { "study_group": "PMID41125326", "status": "present", "id": "PMID 41125326 / DOI 10.1136/ejhpharm-2025-004656", "location": "selected-records.json; frozen evidence report" }, { "study_group": "PMID39379664", "status": "present", "id": "PMID 39379664 / DOI 10.1007/s11095-024-03771-6", "location": "selected-records.json; frozen evidence report" }, { "study_group": "EudraVigilance potential counterfeit ICSRs", "status": "absent", "id": "PMID 42137313 / DOI 10.3389/fphar.2026.1805842", "location": "supplemental primary pharmacovigilance report" }, { "study_group": "follow-on/compounded GLP-1 assays", "status": "absent", "id": "PMID 42533250 / DOI 10.1007/s11095-026-04146-9", "location": "supplemental primary in-vitro report; Consensus fetch JSON saved" } ], "primary_comparison_count": 5, "additional_original_source_receipts": [], "status": "completed_retrospective_original_source_reconciliation", "raw_receipts": [ { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\grey-market-glp1\\consensus-browser-response.md", "sha256": "d792518fd3e300d299f99432d83369658ad17e6c470755d1fc35828616ce4131" }, { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\grey-market-glp1\\browser-thread.json", "sha256": "8cda9b595b1bb07806e221a3718b0270b5f7bb47de08063c5ed488d1805de1ad" }, { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\grey-market-glp1\\consensus-search-raw.json", "sha256": "d42d5b0fc05cd63751148f8329d63ef162bdd4a2d9b3229315365abd95e401d3" }, { "path": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\grey-market-glp1\\consensus-fetch-76090d1d936b5dc3bd8a635ced882462.json", "sha256": "f86d7f9f5607af0b5e69f0294da13549c2479a9a08c7f5a289ab989fc990d313" } ], "manifest_source": "deliverables\\consensus_consistency_audit_2026-10-09\\checks\\grey-market-glp1\\final-structured-consensus-validation.json", "literature_cutoff_preserved": true } }